<DOC>
	<DOC>NCT02088606</DOC>
	<brief_summary>A prospective, multicenter, interventional study to collect confirmatory evidence on the safety and effectiveness of the TactiCath® percutaneous ablation catheter for the treatment of symptomatic paroxysmal atrial fibrillation using contact force assisted irrigated radiofrequency ablation.</brief_summary>
	<brief_title>TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Continued Access Protocol</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>symptomatic PAF (Paroxysmal Atrial Fibrillation)refractory to at least one Class IIV antiarrhythmic drug minimum one documented PAF episode &gt;30 sec duration within prior 12 months minimum three PAF episodes during prior 12 months 18 years or older persistent or longstanding persistent AF(Atrial Fibrillation) four or more cardioversions in prior 12 months MI (myocardial infarction), CABG (coronary artery bypass graft) or PCI (percutaneous coronary intervention) within preceding 3 months left atrial diameter &gt; 5.0 cm LVEF (left ventricular ejection fraction)&lt; 35% NYHA (New York Heart Association) class III or IV previous left atrial ablation procedure previous tricuspid or mitral valve repair surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Atrial fibrillation</keyword>
</DOC>